Zhitong Finance App News, Sains (688480.SH) announced that it plans to use its own capital of 183 million yuan to acquire 61% of the shares of the participating subsidiary Fujian Zijin Mineral Processing Pharmaceutical Co., Ltd. (“Zijin Pharmaceutical”), and plans to sign an agreement to transfer 51% of Zijin Pharmaceutical's shares held by Zijin Mining Group Nanfang Investment Co., Ltd. (“Zijin South”) and 10% of Zijin Pharmaceutical's shares held by Shanghang County Zhongxin Investment Department (“Zhongxin Investment”). After the transaction is completed, the company will hold 100% of Zijin Pharmaceutical's shares.

According to reports, Zijin Pharmaceutical is a technology-based chemical enterprise integrating R&D, production and sales of mineral processing agents and copper extractants. It is mainly used for copper hydrometallurgy production in the non-ferrous industry, and is suitable for processing low-grade copper ore, copper oxide ore, and some complex copper ores. The main products are copper extractants (ZJ988X), environmentally friendly cleaning agents (ZJ601), environmentally friendly inhibitors (ZJ201) and various mineral processing additives. Zijin Pharmaceutical has an annual production capacity of 3,400 tons of copper extractants, 2,000 tons of phosphoric acid extractants, 1,000 tons of lead beneficiation capacity, and technical research and development capabilities for mineral processing additives.

Zijin Pharmaceutical's copper extractant series product models mainly include ZJ988K, ZJ988C, ZJ988A, ZJ988N and ZJ988X. A series of copper extractant products can be customized according to different customer needs, different liquid ingredients, and mixed extractants with different ratios, greatly optimizing the extraction system process, and making full use of the superior properties of oximal and ketoxime.